[vc_row][vc_column width=”1/1″][vc_column_text]

Publications

[/vc_column_text][dt_gap height=”25″][vc_column_text]Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists. Hu, YJ; St.-Onge, M; Laliberte, S; Vallee, F, Jin, S; Bedard, L; Labrecque, J; Albert, JS. Biorg. Med. Chem. Lett., 2014, 24, 3199. Link

Discovery of a series of aryl-N-(3-(alkylamino)-5-(trifluoromethyl)phenyl)benzamides as TRPA1 antagonists. Laliberte, S; Vallee, F; Fournier, PA; Bedard, L; Labrecque, J; Albert, JS. Biorg. Med. Chem. Lett., 2014, 24, 3204. Link

Development of a Plate-Based Optical Biosensor Fragment Screening Methodology to Identify Phosphodiesterase 10A Inhibitors. Geschwindner S, Dekker N, Horsefield R, Tigerstrom A, Johansson P, Scott CW, Albert JS, J. Med. Chem., 2013. Link

Multiple Roles of Transient Receptor Potential (TRP) Channels in Inflammatory Conditions and Current Status of Drug Development, Radresa, O,Paré, M, Albert, JS, 2013, Current Topics in Med. Chem., 2013. Link

Targets and Emerging Therapies for Schizophrenia; 2012, Wiley Publications, Editors: Albert, JS, Wood, MW.Link

Progress in the Exploration and Development of GlyT1 Inhibitors for Schizophrenia; Albert, JS, Wood, MW.;2012. Link

Isoquinucline-based GlyT1 inhibitors for schizophrenia: Discovery, optimization, synthesis, and in vivo pharmacology, Albert, JS; ACS National Symposium, 2012.

Potent and orally efficacious benzothiazole amides as TRPV1 antagonists. Brown, W, Johnstone, S, Jones, P, Walpole, C, Griffin, AW, et al. BMCL, 2012, 22, 6205. Link

N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration. Zhongyong W; Tremblay, M; Johnstone, S; Tomaszewski, M; Brown, W; Walpole, C; Page, D; et al. BMCL, 2012, 22, 3884. Link

Fragment-based lead discovery; Albert, JS, 2010, Wiley Publications.Link

Discovery of new high-affinity PDE10 inhibitors using fragment based lead generation and knowledge-based design, Albert, JS; ACS National Symposium, 2012

Identification of high-affinity β-secretase inhibitors using fragment-based lead generation; Albert, JS, Edwards, PD, 2008.Link

An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca’s drug discovery programmes, Albert, JS; Blomberg, N., et al.Link

Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta -secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency.Edwards, PD; Albert, JS; et al.J. Med. Chem. 2007, 50, 5912-5925. Link

Neurokinin-3 receptor antagonists in schizophrenia, Albert, JS, Potts, W., Expert Opin.Ther. Pat. 2006, 16, 925-937. Link[/vc_column_text][/vc_column][/vc_row]